<DOC>
	<DOCNO>NCT00215800</DOCNO>
	<brief_summary>multi-center , double-blind , randomize , placebo-controlled study safety efficacy .</brief_summary>
	<brief_title>The Study Safety Efficacy Ampligen Chronic Fatigue Syndrome</brief_title>
	<detailed_description>This study prospective , double-blind , randomize , placebo-controlled , equal parallel group study conduct fifteen ( 15 ) center compare safety efficacy Ampligen速 IV versus placebo IV 230-240 patient CFS/ME . Patients randomize stratified receive either Ampligen速 intravenously placebo ( normal saline ) intravenously . Fifty percent ( 50 % ) patient treat Ampligen速 IV 50 % patient treat placebo IV . Patients study 64 week ( STAGES I plus II ) pass : 1 ) remove toxicity , 2 ) withdraw voluntarily , 3 ) change patient 's medical condition make continued participation unsafe , 4 ) patient become non-compliant requirement protocol 4 ) Sponsor terminate study . Official Title : A multi-center , double-blind , randomize , placebo-controlled study safety efficacy poly I : poly C12U ( Ampligen速 ) 400 mg IV twice weekly versus placebo patient severely debilitate chronic fatigue syndrome ( CFS ) /myalgic encephalomyelitis ( ME ) Further Study Details Enrollment = 234 : Study Completed</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Fatigue Syndrome , Chronic</mesh_term>
	<mesh_term>Myalgia</mesh_term>
	<mesh_term>Encephalomyelitis</mesh_term>
	<mesh_term>poly ( I ) .poly ( c12 , U )</mesh_term>
	<mesh_term>Poly I-C</mesh_term>
	<criteria>1 . A diagnosis CFS , define Center Disease Control ( 1988 CDC case definition ) &gt; 12 month ( Appendix D ) . 2 . Age Range : &gt; 18 year old , &lt; 60 year old . 3 . Males nonpregnant , nonlactating female : Females must nonchild bear potential ( either postmenopausal two ( 2 ) year surgically sterile include tubal ligation ) use effective mean contraception ( birth control pill , intrauterine device , diaphragm ) . Females less two ( 2 ) year postmenopausal , tubal ligation use contraception must negative serum pregnancy test within two ( 2 ) week prior first study medication infusion . Females child bear potential agree use effective mean contraception four ( 4 ) week prior baseline pregnancy test four ( 4 ) week last study medication infusion . 4 . A reduced quality life determine documented KPS 40 60 three ( 3 ) occasion , least 14 day apart , twelve ( 12 ) week immediately precede start study drug infusion . The KPS must round increment ten ( 10 ) . 5 . Ability walk ( minimum 20 second ) move treadmill ( grade = 0 % ; belt speed = 1 mph ) minimum two ( 2 ) occasion twelve ( 12 ) week immediately precede study entry . 6 . Laboratory documentation ( baseline historical follow onset CFS/ME ) negative ANA negative antids ( doublestranded ) DNA , negative Rheumatoid Factor , erythrocyte sedimentation rate ( ESR ) . 7 . Laboratory documentation patient euthyroid ( patient thyroid replacement therapy must stable dose eight ( 8 ) week washout period ) base thyroid profile ( T4 , T3 , TSH , T3 uptake Free T4 index ) perform baseline . 8 . Ability provide write informed consent indicate awareness investigational nature study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Chronic Fatigue Syndrome</keyword>
	<keyword>Myalgic Encephalomyelitis</keyword>
	<keyword>CFS</keyword>
	<keyword>Ampligen</keyword>
	<keyword>Poly I : ploy C12U</keyword>
</DOC>